DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: An MS-MLPA approach

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Casadio, Valentina ^a   Molinari, Chiara ^a   Calistri, Daniele ^a   Tebaldi, Michela ^a   Gunelli, Roberta ^b   Serra, Luigi ^b   Falcini, Fabio ^a   Zingaretti, Chiara ^c   Silvestrini, Rosella ^a   Amadori, Dino ^a   Zoli, Wainer ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c National Institute of Molecular Genetics   (Italy)

Author keywords

Gene methylation profile; Non muscle invasive bladder cancer (NMIBC); Recurrence

Indexed keywords

APC PROTEIN; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CASPASE 8; CD44V ANTIGEN; CHECKPOINT WITH FORKHEAD AND RING FINGER DOMAIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEATH ASSOCIATED PROTEIN KINASE 1; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; HYPERMETHYLATED IN CANCER 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN MLH1; PROTEIN P73; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE LOCUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT MONITORING; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PROGNOSIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84887633975     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-94     Document Type: Article

References (28)

1. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Eur Urol 2009 56 3 430 442 10.1016/j.eururo.2009.06.028 19576682.
2. Epigenetics in cancer. Sharma S, Kelly TK, Jones PA, Carcinogenesis 2010 31 1 27 36 10.1093/carcin/bgp220 19752007.
3. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. Tao W, Hongli L, Yeshan C, Wei L, Jing Y, Gang W, J Exp Clin Cancer Res 2009 28 160 10.1186/1756-9966-28- 160 20042089.
4. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. Jian Z, Yuyan W, Jianchun D, Hua B, Zhijie W, Lai W, J Exp Clin Cancer Res 2012 31 80 10.1186/1756-9966-31-80 23009178.
5. Hypermethylation in bladder cancer: biological pathways and translational applications. Sánchez-Carbayo M, Tumour Biol 2012 33 22 347 361 22274923.
6. Epigenetics of bladder cancer. Kim WJ, Kim YJ, Methods Mol Biol 2012 863 111 118 22359289.
7. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. Cabello MJ, Grau L, Franco N, Orenes E, Alvarez M, Blanca A, et al. J Mol Diagn 2011 13 1 29 40 10.1016/j.jmoldx.2010.11.008 21227392.
8. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al. BJU Int 2012 109 6 941 948 10.1111/j.1464-410X.2011.10428.x 21756281.
9. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer. Eissa S, Swellam M, El-Khouly IM, Kassim SK, Shehata H, Mansour A, et al. Cancer Epidemiol Biomarkers Prev 2011 20 8 1657 1664 10.1158/1055-9965.EPI- 11-0237 21680534.
10. DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. Negraes PD, Favaro FP, Camargo JL, Oliveira ML, Goldberg J, Rainho CA, et al. BMC Cancer 2008 8 238 10.1186/1471-2407-8-238 18702824.
11. Tissue inhibitor of metalloproteinases 3 promoter methylation is an independent prognostic factor for bladder cancer. Hoque MO, Begum S, Brait M, Jeronimo C, Zahurak M, Ostrow KL, Rosenbaum E, J Urol 2008 179 2 743 747 10.1016/j.juro.2007.09.019 18082200.
12. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, et al. Eur J Cancer 2005 41 17 2769 2778 10.1016/j.ejca.2005.07.019 16242928. (Pubitemid 41607571)
13. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, et al. Cancer Res 2002 62 14 4048 4053 12124340. (Pubitemid 34791073)
14. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection. Lin HH, Ke HL, Wu WJ, Lee YH, Chang LL, Urol Oncol 2012 30 2 177 181 10.1016/j.urolonc.2010.01.002 20800513.
15. Promoter hypermethylation identifies progression risk in bladder cancer. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al. Clin Cancer Res 2007 13 7 2046 2053 10.1158/1078-0432.CCR-06-2476 17404085. (Pubitemid 46649871)
16. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G, Nucleic Acids Res 2002 30 12 57 10.1093/nar/gnf056 12060695.
17. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, et al. Nucleic Acids Res 2005 33 14 128 10.1093/nar/gni127 16106041. (Pubitemid 41222585)
18. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, et al. J Transl Med 2010 8 86 10.1186/1479-5876-8-86 20849603.
19. Methylation profiling of rectal cancer identifies novel markers of early-stage disease. Leong KJ, Wei W, Tannahill LA, Caldwell GM, Jones CE, Morton DG, et al. Br J Surg 2011 98 5 724 734 10.1002/bjs.7422 21360524.
20. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. Moelans CB, Verschuur-Maes AH, Van Diest PJ, J Pathol 2011 225 2 222 231 10.1002/path.2930 21710692.
21. Altered methylation at microRNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach. Pavicic W, Perkiö E, Kaur S, Peltomäki P, Mol Med 2011 17 7-8 726 735 21327300.
22. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, Peltomäki P, Cancer Res 2008 68 12 4597 4605 10.1158/0008-5472.CAN-07-6645 18559504.
23. HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Fleuriel C, Touka M, Boulay G, Guérardel C, Rood BR, Leprince D, Int J Biochem Cell Biol 2009 41 1 26 33 10.1016/j.biocel.2008.05.028 18723112.
24. Enhanced GSTP1 expression in transitional cell carcinoma of urinary bladder is associated with altered apoptotic pathways. Pljesa-Ercegovac M, Savic-Radojevic A, Dragicevic D, Mimic-Oka J, Matic M, Sasic T, Pekmezovic T, Urol Oncol 2011 29 1 70 77 10.1016/j.urolonc.2008.10.019 19162514.
25. Tumorigenic and prognostic significance of RASSF1A expression in Low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer. Ha YS, Jeong P, Kim JS, Kwon WA, Kim IY, Yun SJ, Urology 2012 79 6 1 e6 1411.
26. Epigenetic markers as promising prognosticators for bladder cancer. Kim YK, Kim WJ, Int J Urol 2009 16 1 17 22 10.1111/j.1442-2042.2008.02143.x 18721202.
27. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Serizawa RR, Ralfkiaer U, Steven K, Lam GW, Schmiedel S, Schüz J, et al. Int J Cancer 2011 129 1 78 87 10.1002/ijc.25651 20824703.
28. Mechanisms of recurrence of Ta/T1 bladder cancer. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM, et al. Ann R Coll Surg Engl 2010 92 6 519 524 10.1308/003588410X12664192076935 20522307.